Pembrolizumab improves OS in firstline treatment for unresectable advanced pleural mesothelioma

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for unresectable advanced ...Подробнее

Discussion of the results from the BEAT-meso trial in pleural mesotheliomaПодробнее

PROMISE-meso: pembrolizumab vs. standard chemotherapy for mesotheliomaПодробнее

Phase I/II study of pembrolizumab + binimetinib in unresectable locally advanced or metastatic TNBCПодробнее

Resectable mesothelioma #2023 #oncology #lungcancerПодробнее

Pembrolizumab showed clinical benefit in malignant pleural mesotheliomaПодробнее

Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expressionПодробнее

Mesothelioma: KEYTRUDA® / Pembrolizumab + Chemo Receives FDA ApprovalПодробнее

BEAT-meso: Phase III trial of bevacizumab and chemo ± atezolizumab for advanced pleural mesotheliomaПодробнее

malignant pleural mesothelioma treatmentПодробнее

PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural mesotheliomaПодробнее

Pembrolizumab works better than chemotherapy alone as initial treatment for NSCLCПодробнее

SYSTEMS-2: higher dose of radiotherapy increases life expectancy for malignant pleural mesotheliomaПодробнее

What is the preferred therapy for malignant pleural mesothelioma?Подробнее

Keytruda Proves Effectiveness for MesotheliomaПодробнее

Mesothelioma Chemotherapy: Inez’s ExperienceПодробнее

New treatment avenues in malignant mesotheliomaПодробнее

Improved Survival in Malignant Pleural Mesothelioma with Avastin Added to ChemotherapyПодробнее

Pembrolizumab plus chemo as firstline therapy for NSCLCПодробнее